Patrick P. Gleason

2.0k total citations · 1 hit paper
48 papers, 1.5k citations indexed

About

Patrick P. Gleason is a scholar working on Economics and Econometrics, Family Practice and Geriatrics and Gerontology. According to data from OpenAlex, Patrick P. Gleason has authored 48 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 14 papers in Family Practice and 11 papers in Geriatrics and Gerontology. Recurrent topics in Patrick P. Gleason's work include Medication Adherence and Compliance (14 papers), Pharmaceutical Economics and Policy (12 papers) and Pharmaceutical Practices and Patient Outcomes (11 papers). Patrick P. Gleason is often cited by papers focused on Medication Adherence and Compliance (14 papers), Pharmaceutical Economics and Policy (12 papers) and Pharmaceutical Practices and Patient Outcomes (11 papers). Patrick P. Gleason collaborates with scholars based in United States, Canada and New Zealand. Patrick P. Gleason's co-authors include Michael J. Fine, Thomas P. Meehan, Jonathan M. Fine, Deron Galusha, Catherine I. Starner, Jeremy A Schafer, Alan Heaton, Brent W. Gunderson, Soma Sen and Yang Qiu and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and The American Journal of Medicine.

In The Last Decade

Patrick P. Gleason

46 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes

2024 55 citations Patrick P. Gleason, Benjamin Y. Urick et al. Journal of Managed Care & Specialty Pharmacy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick P. Gleason United States	18	640	249	244	177	173	48	1.5k
Jeffrey S. McCombs United States	25	680 1.1×	213 0.9×	369 1.5×	131 0.7×	91 0.5×	58	2.3k
R. Janknegt Netherlands	20	271 0.4×	71 0.3×	161 0.7×	209 1.2×	127 0.7×	80	1.3k
Ronald A. Schoenenberger Switzerland	16	831 1.3×	273 1.1×	74 0.3×	65 0.4×	347 2.0×	34	1.6k
Jacob T. Painter United States	20	283 0.4×	108 0.4×	98 0.4×	234 1.3×	79 0.5×	84	1.1k
John‐Michael Gamble Canada	24	334 0.5×	138 0.6×	98 0.4×	101 0.6×	49 0.3×	81	1.8k
Kim C. Coley United States	19	233 0.4×	71 0.3×	128 0.5×	243 1.4×	65 0.4×	70	1.8k
Kelly R. Reveles United States	22	636 1.0×	91 0.4×	54 0.2×	97 0.5×	181 1.0×	88	1.4k
Samuel Campbell Canada	21	284 0.4×	270 1.1×	66 0.3×	39 0.2×	153 0.9×	67	1.1k
Douglas Steinke United Kingdom	27	373 0.6×	69 0.3×	165 0.7×	115 0.6×	31 0.2×	92	1.9k
Maryann Mazer‐Amirshahi United States	24	200 0.3×	371 1.5×	201 0.8×	170 1.0×	67 0.4×	133	1.8k

Countries citing papers authored by Patrick P. Gleason

Since Specialization

Citations

This map shows the geographic impact of Patrick P. Gleason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick P. Gleason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick P. Gleason more than expected).

Fields of papers citing papers by Patrick P. Gleason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick P. Gleason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick P. Gleason. The network helps show where Patrick P. Gleason may publish in the future.

Co-authorship network of co-authors of Patrick P. Gleason

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick P. Gleason. A scholar is included among the top collaborators of Patrick P. Gleason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick P. Gleason. Patrick P. Gleason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kenney, James T. & Patrick P. Gleason. (2025). Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey. Journal of Managed Care & Specialty Pharmacy. 31(2-a Suppl). S20–S24. 1 indexed citations

Gleason, Patrick P., et al.. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy. 30(8). 860–867. 55 indexed citations breakdown →

Burke, J. P., et al.. (2023). Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria. Journal of Managed Care & Specialty Pharmacy. 29(8). 941–951. 2 indexed citations

Starner, Catherine I., et al.. (2023). Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis. Journal of Managed Care & Specialty Pharmacy. 29(6). 599–606. 11 indexed citations

Ollendorf, Daniel A., Sachin Kamal‐Bahl, Patrick P. Gleason, Suzanne Schrandt, & Newell E. McElwee. (2019). Practical Next Steps in Improving Value Measurement and Use. Value in Health. 22(6). S29–S31. 1 indexed citations

Starner, Catherine I., Yang Qiu, Pinar Karaca‐Mandic, & Patrick P. Gleason. (2016). Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort Study. Journal of Managed Care & Specialty Pharmacy. 22(12). 1403–1410. 6 indexed citations

Borah, Bijan J., Yang Qiu, Nilay D. Shah, & Patrick P. Gleason. (2016). Impact of provider mailings on medication adherence by Medicare Part D members. Healthcare. 4(3). 207–216. 5 indexed citations

Ha, Austin Y., Patrick P. Gleason, Jonathan Winkler, et al.. (2016). Cryoglobulinemic membranoproliferative glomerulonephritis associated with mucosaassociated lymphoid tissue lymphoma treated with rituximab. PubMed. 4. 1–4. 2 indexed citations

Gleason, Patrick P., G. Caleb Alexander, Catherine I. Starner, et al.. (2013). Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions. Journal of Managed Care Pharmacy. 19(7). 542–548. 42 indexed citations

10.

Starner, Catherine I., et al.. (2012). Rosiglitazone Prior Authorization Safety Policy: A Cohort Study. Journal of Managed Care Pharmacy. 18(3). 225–233. 12 indexed citations

11.

Starner, Catherine I., et al.. (2009). Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly. The American journal of geriatric pharmacotherapy. 7(1). 11–19. 17 indexed citations

12.

Shrank, William H., Patrick P. Gleason, Claire Canning, et al.. (2009). Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications? An Evaluation of the Target Pharmacy Label. Journal of General Internal Medicine. 24(5). 570–578. 28 indexed citations

13.

Shrank, William H., Amanda R. Patrick, Patrick P. Gleason, et al.. (2009). An Evaluation of the Relationship Between the Implementation of a Newly Designed Prescription Drug Label at Target Pharmacies and Health Outcomes. Medical Care. 47(9). 1031–1035. 17 indexed citations

14.

Starner, Catherine I., Jeremy A Schafer, Alan Heaton, & Patrick P. Gleason. (2008). Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events. Journal of Managed Care Pharmacy. 14(6). 523–531. 84 indexed citations

15.

Gleason, Patrick P. & Allen F. Shaughnessy. (2007). Telithromycin (Ketek) for Treatment of Community-Acquired Pneumonia. American family physician. 76(12). 1857. 3 indexed citations

16.

Gunderson, Brent W., et al.. (2007). Utilization, Cost Trends, and Member Cost - Share for Self-Injectable Multiple Sclerosis Drugs-Pharmacy and Medical Benefit Spending From 2004 Through 2007. Journal of Managed Care Pharmacy. 13(9). 799–806. 14 indexed citations

17.

Gleason, Patrick P., et al.. (2005). Medical and Pharmacy Expenditures After Implementation of a Cyclooxygenase‐2 Inhibitor Prior Authorization Program. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(7). 924–934. 16 indexed citations

18.

Gleason, Patrick P., et al.. (2001). Elevation of Hepatic Transaminases after Enoxaparin Use: Case Report and Review of Unfractionated and Low‐Molecular‐Weight Heparin‐Induced Hepatotoxicity. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(1). 108–113. 60 indexed citations

19.

Gleason, Patrick P., Thomas P. Meehan, Jonathan M. Fine, Deron Galusha, & Michael J. Fine. (1999). Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With Pneumonia. Archives of Internal Medicine. 159(21). 2562–2562. 377 indexed citations

20.

Gleason, Patrick P., Richard Schulz, Nicholas L. Smith, et al.. (1998). Correlates and prevalence of benzodiazepine use in community-dwelling elderly. Journal of General Internal Medicine. 13(4). 243–250. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact